Development of functionally selective agonists as novel therapeutic agents

Kelly A. Berg; William P. Clarke

doi:10.1016/j.ddstr.2006.10.017

Development of functionally selective agonists as novel therapeutic agents

Kelly A. Berg, William P. Clarke

Department of Pharmacology

Producción científica: Review article › revisión exhaustiva

24 Citas (Scopus)

Resumen

Traditionally, drug selectivity has been attributed solely to differential affinity for different receptor subtypes. Recent experimental evidence suggests that, in addition to receptor subtype selectivity, drugs may be selective for individual signaling pathways coupled to a single receptor subtype. This 'functional selectivity' holds the promise of improved therapeutic selectivity and reduced adverse effects.

Idioma original	English (US)
Páginas (desde-hasta)	421-428
Número de páginas	8
Publicación	Drug Discovery Today: Therapeutic Strategies
Volumen	3
N.º	4
DOI	https://doi.org/10.1016/j.ddstr.2006.10.017
Estado	Published - jun 2006

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery

Acceder al documento

10.1016/j.ddstr.2006.10.017

Otros archivos y enlaces

Citar esto

@article{21d7407545c54a629a797ccd666ba323,

title = "Development of functionally selective agonists as novel therapeutic agents",

abstract = "Traditionally, drug selectivity has been attributed solely to differential affinity for different receptor subtypes. Recent experimental evidence suggests that, in addition to receptor subtype selectivity, drugs may be selective for individual signaling pathways coupled to a single receptor subtype. This 'functional selectivity' holds the promise of improved therapeutic selectivity and reduced adverse effects.",

author = "Berg, {Kelly A.} and Clarke, {William P.}",

year = "2006",

month = jun,

doi = "10.1016/j.ddstr.2006.10.017",

language = "English (US)",

volume = "3",

pages = "421--428",

journal = "Drug Discovery Today: Therapeutic Strategies",

issn = "1740-6773",

publisher = "Elsevier Ltd",

number = "4",

}

TY - JOUR

T1 - Development of functionally selective agonists as novel therapeutic agents

AU - Berg, Kelly A.

AU - Clarke, William P.

PY - 2006/6

Y1 - 2006/6

N2 - Traditionally, drug selectivity has been attributed solely to differential affinity for different receptor subtypes. Recent experimental evidence suggests that, in addition to receptor subtype selectivity, drugs may be selective for individual signaling pathways coupled to a single receptor subtype. This 'functional selectivity' holds the promise of improved therapeutic selectivity and reduced adverse effects.

AB - Traditionally, drug selectivity has been attributed solely to differential affinity for different receptor subtypes. Recent experimental evidence suggests that, in addition to receptor subtype selectivity, drugs may be selective for individual signaling pathways coupled to a single receptor subtype. This 'functional selectivity' holds the promise of improved therapeutic selectivity and reduced adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=33846211115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846211115&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2006.10.017

DO - 10.1016/j.ddstr.2006.10.017

M3 - Review article

AN - SCOPUS:33846211115

SN - 1740-6773

VL - 3

SP - 421

EP - 428

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

IS - 4

ER -

Development of functionally selective agonists as novel therapeutic agents

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto